Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: "Even though the majority of strokes and heart attacks occur in people who are 65 and older, studies have found that cholesterol-lowering drugs are not prescribed as often for older people as they are for younger people," Dr. Seemant Chaturvedi of Wayne State University in Detroit, Michigan, said in a statement. "These results show that using these drugs is just as beneficial for people who are over 65 as they are for younger people." In April, British researchers reported in the New England Journal of Medicine that treating high blood pressure in people 80 and older cut their risk of fatal strokes and other heart problems. Statins cut the risk of heart attack or stroke by lowering levels of fatty substances such as low-density lipoprotein, or "bad" cholesterol, and triglycerides. They also raise levels of high-density lipoprotein or "good" cholesterol. They include atorvastatin, made by Pfizer Inc under the brand name Lipitor; pravastatin or Pravachol, made by Bristol-Myers Squibb; fluvastatin, made by Novartis AG under the brand name Lescol, and several others. Seemant and colleagues studied 4,731 people 18 and older who had a recent stroke or a mini-stroke as part of a study sponsored by Pfizer. About half were over 65, with an average age of 72. The other half were under 65 and had an average age of 54. In each age group, about half were taking Lipitor and the other half were on a placebo. The statin worked equally well in both groups, the researchers reported in the journal Neurology. It lowered LDL cholesterol by about 61 points in the group of older patients and by about 59 points in the younger age group. Stroke is the No. 3 killer in the United States behind heart disease and cancer. The U.S. Centres for Disease Control and Prevention estimate 780,000 Americans will have strokes this year. They will kill 150,000 people and permanently disable 15 percent to 30 percent of survivors. Claim: Statins fight stroke in older people too.
[A]: Older people who have had a stroke or mini-stroke benefit from cholesterol-lowering statin drugs just as much as younger people do, U.S. researchers said on Wednesday.

[Q]: Paragraph: In May 2020, as demonstrators in various parts of the U.S. continued to advocate for the lessening of social-distancing measures and forced business closures enacted to combat the spread of the coronavirus pandemic, social media users circulated the following photograph, said to have been taken at an "end the lockdown" protest: Many viewers found the protester's sign equating the mandatory wearing of personal protective equipment (PPE) such as face masks to muzzles worn by dogs or slaves to be insulting, and they questioned whether this image was authentic or whether the wording of the sign had been digitally altered. Claim: "A photograph shows a protester against pandemic stay-at-home orders holding a sign declaring that ""muzzles are for dogs and slaves."
[A]: But the photograph is indeed real, and was taken at a protest on May 15, 2020, against California's stay-at-home order staged at the Humboldt County courthouse in Eureka, California. Kym Kemp's Redheaded Blackbeltblog features the original photograph, along with a snapshot of another demonstrator holding the same sign.

[Q]: Paragraph: The European Medicine Agency (EMA) also backed a new drug from Dainippon Sumitomo Pharma called Latuda, for the treatment of schizophrenia, and Bemfola, a new biosimilar medicine for the treatment of infertility. But the regulator decided against recommending Teva's new multiple sclerosis (MS) pill Nerventra, or laquinimod, which the Israeli firm is developing with Swedish partner Active Biotech, and recommended rejecting an application from Swiss drugmaker Novartis to market its heart failure drug serelaxin. Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months. The prospects for laquinimod were already viewed by analysts as uncertain, since the drug missed its main goal in a late-stage trial in 2011 and U.S. regulators have asked for another Phase III study before considering it. Analysts at Jefferies in London said the rejection of Teva's MS drug was as they had expected and was driven by three major concerns - about the possible link to risk of cancers and pregnancy dangers, and its modest effect on relapse rates which suggested an unfavorable risk-benefit balance for the drug. On Bayer's Adempas, the EMA said the key benefits of the drug were "its ability to provide significant improvement in exercise capacity and pulmonary haemodynamics in two specific conditions known as chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension." Adempas, which belongs to a class of drugs known as soluble guanylate cyclase stimulators that help arteries relax to increase blood flow and decrease blood pressure, got backing from drugs regulators in United States in October last year, and in Japan earlier this month. The EMA also issued negative opinions for two so-called orphan medicines - Masiviera from France's AB Science, intended for certain types of advanced pancreatic cancer, and Translarna, from PTC Therapeutics, designed to treat Duchenne muscular dystrophy. GSK's once-weekly diabetes drug albiglutide won the EMA's recommendation and will be sold under the brand name Eperzan. It belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, as well as Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca. Last year regulators in the United States pushed back an approval decision on the drug until April 15. Claim: EU regulator backs Bayer, GSK drugs, knocks back Novartis, Teva.
[A]:
Europe's drugs regulator gave its backing on Friday for marketing approval to be granted for Bayer's pulmonary hypertension drug Adempas and for GlaxoSmithKline's diabetes medicine Eperzan.